ORY — ORYZON Genomics SA Cashflow Statement
0.000.00%
Last trade - 00:00- €211.61m
- €190.88m
Annual cashflow statement for ORYZON Genomics SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -7.18 | -6.56 | -6.1 | -5.57 | -5.6 |
| Depreciation | |||||
| Non-Cash Items | 0.23 | 1.11 | 1.84 | 1.08 | 0.911 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.18 | 3.43 | 3.54 | -1.35 | 2.2 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -3.63 | -1.85 | -0.575 | -5.69 | -2.36 |
| Capital Expenditures | -11.8 | -14.3 | -14.5 | -7.71 | -11 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.037 | -0.001 | -0.001 | -0.102 | -0.058 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -11.7 | -14.3 | -14.5 | -7.81 | -11 |
| Financing Cash Flow Items | 0 | 0.144 | 0.076 | 1.58 | 4.36 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 4.12 | 8.71 | 6.02 | 6.87 | 36.1 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -10.9 | -7.41 | -9.06 | -6.64 | 22.7 |